Oppenheimer analyst Jay Olson maintains $Marinus Pharmaceuticals (MRNS.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 12.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Marinus Pharmaceuticals (MRNS.US)$'s main analysts recently are as follows:
Marinus Pharmaceuticals' Phase III study of oral ganaxolone in tuberous sclerosis complex rare epilepsy did not achieve the primary endpoint, failing to show a significant difference in placebo-adjusted percent change. Despite this, the company may still find 'leverageability' in its revenue stream from CDD. Following the stock's significant decline, there could potentially be an arbitrage opportunity.
The revision of the outlook on Marinus Pharmaceuticals to a more cautious stance comes in the wake of the Phase III trial of ganaxolone in tuberous sclerosis complex not achieving its primary endpoint. This outcome is coupled with the company's reported financial limitations and the indeterminate schedule for future actions.
Marinus Pharmaceuticals' Phase III trial of oral ganaxolone in treating tuberous sclerosis complex, a type of rare epilepsy, did not achieve its primary goal of reducing seizures. With no immediate catalysts anticipated until 2025, the outlook on the company has become more conservative.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奥本海默控股分析师Jay Olson维持$Marinus Pharmaceuticals (MRNS.US)$买入评级。
根据TipRanks数据显示，该分析师近一年总胜率为38.6%，总平均回报率为12.4%。
此外，综合报道，$Marinus Pharmaceuticals (MRNS.US)$近期主要分析师观点如下：
Marinus Pharmaceuticals的口服甘力醇用于结节性硬化症罕见癫痫病的第三阶段研究未达到主要终点，未能显示出显著的安慰剂调整百分比变化差异。尽管如此，该公司仍可能从CDD的营业收入中找到“杠杆能力”。股价大幅下跌后，可能存在套利机会。
Marinus Pharmaceuticals的前景展望修订为更为谨慎的立场，是因在结节性硬化症中甘力醇的第三阶段试验未达到主要终点。这一结果与该公司报告的财务限制以及未来行动的不确定时间表相关。
Marinus Pharmaceuticals在治疗结节性硬化症，一种罕见的癫痫病目的口服甘力醇的第三期试验未能实现减少癫痫发作的主要目标。预计直到2025年都没有即期触发因素，该公司前景更加保守。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
